Loading...
•
Jun 30, 2021
Iovance Q2 2021 Earnings Report
Reported second quarter 2021 financial results and corporate updates.
Key Takeaways
Iovance Biotherapeutics reported a net loss of $81.4 million, or $0.53 per share, for the second quarter ended June 30, 2021. The company held $708.7 million in cash, cash equivalents, investments and restricted cash at June 30, 2021. Research and development expenses were $62.1 million, and general and administrative expenses were $19.3 million for the quarter.
Advanced TIL pipeline and presented clinical data across multiple solid tumor indications and treatment settings.
Confident in the broad potential for TIL as the next class of paradigm-shifting therapy for cancer patients.
Cash position as of the second quarter is expected to be sufficient for more than two years based on the current operating plan.
Balance sheet remains strong to advance operating plan, including launch preparations and pipeline development.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...